IR@PKUHSC  > 北京大学第二临床医学院  > 胸外科
学科主题临床医学
Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients
Zhao, Xiao1; Han, Ru-Bing1; Zhao, Jing1; Wang, Jun2; Yang, Fan2; Zhong, Wei1; Zhang, Li1; Li, Long-Yun1; Wang, Meng-Zhao1
关键词Epidermal Growth Factor Receptor Mutation Non-small Cell Lung Cancer Plasma
刊名RESPIRATION
2013
DOI10.1159/000338790
85期:2页:119-125
收录类别SCI
文章类型Article
WOS标题词Science & Technology
类目[WOS]Respiratory System
研究领域[WOS]Respiratory System
关键词[WOS]EGFR MUTATIONS ; CIRCULATING DNA ; GEFITINIB ; SERUM ; TUMOR ; CHEMOTHERAPY ; PREDICTOR ; ERLOTINIB ; ASSAY ; GENE
英文摘要

Background: Epidermal growth factor receptor (EGFR) mutations play essential roles in the treatment of non-small cell lung cancer (NSCLC) patients using EGFR tyrosine kinase inhibitors. Detection of EGFR mutations in blood cell-free DNA (cfDNA) seems promising. However, the mutation status in the plasma/serum is not always consistent with that in the tissues. Objectives: The aims of this study were to compare the mutation statuses in plasma to those in tissues and thus to determine the specific subgroups of NSCLC patients who may be the best candidates for EGFR mutation analyses using blood cfDNA. Methods: A total of 111 pairs of tissue and plasma samples were collected. Mutant-enriched PCR and sequencing analyses were performed to detect EGFR exon 19 deletions and exon 21 L858R mutations. Results: Mutations were discovered in 43.2% (48/111) of the patients. The overall rate of consistency of the EGFR mutation statuses for the 111 paired plasma and tissue samples was 71.2% (79/111). The sensitivity and specificity rates of detecting EGFR mutations in the plasma were 35.6% (16/45) and 95.5% (63/66), respectively. The disease stage and tumor differentiation subgroups showed significantly different detection sensitivities; the sensitivity was 10% in early-stage patients and 56% in advanced-stage patients (p = 0.0014). For patients with poorly differentiated tumors, the sensitivity was 77.8%, which was significantly different from those with highly differentiated (20%; p = 0.0230) and moderately differentiated tumors (19%; p = 0.0042). Conclusion: Blood analyses for EGFR mutations may be effectively used in advanced-stage patients or patients with poorly differentiated tumors. Copyright (C) 2012 S. Karger AG, Basel

语种英语
WOS记录号WOS:000316997500006
资助机构Peking Union Medical College Hospital
引用统计
被引频次:69[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/57186
专题北京大学第二临床医学院_胸外科
北京大学基础医学院
作者单位1.Chinese Acad Med Sci, Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Resp Dis, Beijing 100730, Peoples R China
2.Peking Univ, Dept Thorac Surg, Peoples Hosp, Beijing 100871, Peoples R China
推荐引用方式
GB/T 7714
Zhao, Xiao,Han, Ru-Bing,Zhao, Jing,et al. Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients[J]. RESPIRATION,2013,85(2):119-125.
APA Zhao, Xiao.,Han, Ru-Bing.,Zhao, Jing.,Wang, Jun.,Yang, Fan.,...&Wang, Meng-Zhao.(2013).Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients.RESPIRATION,85(2),119-125.
MLA Zhao, Xiao,et al."Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients".RESPIRATION 85.2(2013):119-125.
条目包含的文件
文件名称/大小 文献类型 版本类型 开放类型 使用许可
Comparison of Epider(181KB)期刊论文出版稿开放获取CC BY-NC-SA浏览 请求全文
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Zhao, Xiao]的文章
[Han, Ru-Bing]的文章
[Zhao, Jing]的文章
百度学术
百度学术中相似的文章
[Zhao, Xiao]的文章
[Han, Ru-Bing]的文章
[Zhao, Jing]的文章
必应学术
必应学术中相似的文章
[Zhao, Xiao]的文章
[Han, Ru-Bing]的文章
[Zhao, Jing]的文章
相关权益政策
暂无数据
收藏/分享
文件名: Comparison of Epidermal Growth Factor Receptor Mutation Statuses in Tissue and Plasma in Stage I-IV Non-Small Cell Lung Cancer Patients.pdf
格式: Adobe PDF
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。